Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
For Privately Owned Skyhawk, Alliance One Of Many Collaborations
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
